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Narcolepsy is a debilitating sleep disorder that presents with excessive daytime sleepiness
(EDS) and cataplexy, which is a sudden paralysis of muscle tone triggered by strong
emotions such as laughing. It is also associated with many other disorders, including
psychiatric disorders, neurologic illnesses, and medication side effects. Common causes
of delayed and incorrect diagnoses of these conditions include lack of physician
familiarity with narcolepsy symptoms and comorbidities which mask narcolepsy signs and
symptoms. Current pharmacologic therapies include Modafinil and Armodafinil for EDS
and sodium oxybate for cataplexy. This review discusses the epidemiology,
pathophysiology, risk factors, presentation, treatment of narcolepsy, and the role of a
novel drug, Pitolisant, in the treatment of EDS in adults with narcolepsy. Pitolisant is a
histamine-3 receptor (H3R), competitive antagonist, and inverse agonist, acting through
the histamine system to regulate wakefulness. It is a novel drug approved in August 2019
by the FDA, is not classified as a controlled substance, and is approved for use in Europe
and the United States to treat EDS and cataplexy in narcolepsy. Recent phase II and III
trials have shown that Pitolisant helps reduce the ESS score and cataplexy. In summary,
based on comparative studies, recent evidence has shown that Pitolisant is non-inferior to
Modafinil in the treatment of EDS but superior to Modafinil in reducing cataplexy.

INTRODUCTION
Narcolepsy is a disabling neurological disorder characterized by excessive daytime sleepiness (EDS) and disturbed
nighttime sleep.1 It is estimated that 1 in every 2000 individuals is affected by narcolepsy, and about half are undiagnosed.1 The onset of narcolepsy is in adolescence or early
adulthood; however, diagnosis is usually delayed by 8-12
years.2 Common causes of delayed and incorrect diagnoses
include lack of physician familiarity with narcolepsy symptoms and comorbidities that mask narcolepsy symptoms.1,3
The International Classification of Sleep Disorder (ICSD)
has categorized narcolepsy into two subtypes: Narcolepsy
Type 1 (NT1) and Narcolepsy Type 2 (NT2).2 NT1 is caused
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by an extensive loss of hypothalamic neurons that produce
hypocretin 1 and 2, which are neuropeptides responsible
for regulating sleepiness and wakefulness.2,4 NT1 and NT2
share a clinical profile; however, patients with NT1classically present with cataplexy, sudden paralysis of muscle
tone triggered by strong emotions such as laughing.1,2 EDS
is defined as unintentional sleepiness, or the inability to
maintain desired wakefulness, which affects one’s functional ability.5 A common cause of EDS is insufficient sleep;
however, EDS is also a symptom and manifestation of medical disorders (narcolepsy, obstructive sleep apnea (OSA),
restless leg syndrome, major depressive disorder, stroke,
Parkinson’s disease, traumatic brain injury, neurologic lesion, and bipolar disorder).5 Prescription and over-thecounter medications that can cause EDS includes beta-
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blockers,
sedative/hypnotics,
anticonvulsants,
and
opioids.5 Lack of sleep and/or inability to maintain wakefulness leads to reduced quality of life and a potentially unsafe
working environment with public safety risks.5 Treatment
of narcolepsy involves pharmacologic and non-pharmacologic interventions, with the primary aim of increasing
wakefulness and reducing cataplexy attacks.6 Non-pharmacologic interventions include scheduled napping, proper
sleep hygiene, and avoidance of drugs that induce daytime
sleepiness.6 Wake-promoting agents, such as Modafinil and
Armodafinil, are first-line pharmacotherapies for EDS in
narcolepsy.6 The exact mechanism of action in promoting
wakefulness is elusive, but there appears to be an increase
in dopaminergic signaling via blocking dopamine reuptake.6 Solriamfetol, norepinephrine, and dopamine reuptake inhibitor are indicated to improve wakefulness in EDS
among individuals with narcolepsy or OSA.7
Pitolisant is a novel noncontrolled drug approved by the
Food and Drug Administration (FDA) in August 2019 to
treat EDS in adults with narcolepsy. Pitolisant is a histamine-3 receptor (H3R), competitive antagonist, and inverse
agonist, acting through the histamine system to regulate
wakefulness.6,7 This review will discuss the epidemiology,
pathophysiology, risk factors, presentation, and treatment
of narcolepsy. Further, we will discuss drug information,
mechanism of action, pharmacokinetics, and pharmacodynamics of Pitolisant. Finally, we will compare several
Pitolisant clinical trials to determine safety and efficacy.

METHODS
We conducted literature searches using PubMed and Google
Scholar between (insert date here). Articles were chosen
based on relevance to pitolisant and its therapeutic effects
on narcolepsy. We selected primary literature as well as
clinical trial studies to reflect the validity of the review.
Older articles were included as well to refer to previous
background information.
The PubMed and Google Scholar keywords searched were
as follows: pitolisant, narcolepsy, excessive daytime sleepiness, NT1, NT2, and histapine-3 receptor.

EPIDEMIOLOGY
Given the delay in diagnosing and masking symptoms with
comorbidities, the prevalence and incidence of narcolepsy
across ages, ethnicities, and genders have been difficult to
estimate. A recent cross-sectional study in the United
States between 2008-2010 shows that the prevalence of narcolepsy was disproportional within age and gender.8 According to this study, the overall prevalence of narcolepsy is
79.4/100,000 persons, with females having a greater prevalence (91.8/100,000 persons) compared to males (65.8/
100,000 persons).9 Ages 21-30 have the highest prevalence
(128.5/100,000), and females within this category have a
higher prevalence than males.9 Patients with narcolepsy
have a high burden of psychiatric comorbidities, with the
greatest prevalence in anxiety and mood disorders in
younger age groups.3 A recent retrospective study,
2008-2010, shows a 1.5 fold excess mortality in narcoleptic

patients vs. a non-narcoleptic population.10 Mortality rates
in 2008 (1.14%), 2009 (1.17%) and 2010 (1.16%) were substantially higher compared to the non-narcoleptic population: 2008 (0.78%), 2009 (0.77%), and 2010 (0.79%).10 In the
narcoleptic population, the highest mortality rates were observed among younger age groups, and the lowest mortality
rates were among the older age group.10

RISK FACTORS
Risk factors for narcolepsy include age, genetics, family history, environmental risk, and psychiatric comorbidities.11
Genetic factors, such as human leukocyte antigen (HLA),
play a role in developing NT1.2 The HLA-DQB1*06:02 allele
is the main genetic risk factor in 86-98% of NT1 patients.2
HLA-DQB1*06:02 positivity is higher in African Americans
(91%) vs. other groups (Caucasian, 76%, Asian, 80%, Latino,
65%), which positively correlates with an earlier age of onset of narcolepsy.12 The H1N1 influenza pandemic between
2009 and 2010 resulted in a spike of narcolepsy among children and teenagers in Scandinavia, Europe, and China.2,4
This surge, particularly in Europe and Scandinavia, was
linked to a vaccine against H1N1 (Pandemrix), which affected children and teenagers with the HLA-DQB1*06:02
gene.2,4 This suggests that the combination of the HLADQB1*06:02 allele, young age, and particular immune stimuli increase the risk of narcolepsy.4 Most cases of narcolepsy
are sporadic; however, first-degree relatives are at higher
risk of developing narcolepsy than the general population.2

PATHOPHYSIOLOGY
Recent studies regarding the pathophysiology of narcolepsy
mostly focus on the selective neuronal loss of orexin-A and
orexin B, synonymously, hypocretin 1, and hypocretin 2,
respectively.13 Orexins are small neuropeptides produced
solely in the lateral hypothalamus, stabilizing sleep-wakefulness and regulating rapid eye movement (REM)
sleep.13,14 The mechanism by which orexin levels decrease
is not understood, but emerging evidence suggests an autoimmune process.13 Selective loss of orexin neurons is a
distinctive phenotype widely associated with narcolepsy
with cataplexy (NT1) due to a decrease in cerebrospinal
fluid (CSF) orexin level compared to NT2 with normal CSF
orexin level.13 Neurologically, orexin-A and orexin-B have
an excitatory effect on postsynaptic neurons via the
orexin-1 receptor (OX1R) and orexin-2 receptor (OX2R).
This excites wake-promoting neurons in the basal forebrain
(BF), tuberomammillary nucleus (TMN), pedunculopontine,
and laterodorsal tegmental nuclei (PPT–LDT), dorsal raphe
(DR), and locus coeruleus (LC).13 Orexin neurons also prevent muscle paralysis during the wakeful period by activating ventrolateral periaqueductal grey and lateral pontine
tegmentum (vlPAG–LPT), DR, and LC, which inhibit the
sublaterodorsal nucleus (SLD).13,14 SLD drives muscle
paralysis during REM sleep by inhibiting motor neurons
through GABAergic premotor neurons.13 In narcolepsy, the
absence of orexin leads to the loss of the excitatory drive to
activate wake-promoting neurons, coupled with decreased
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SLD inhibition. These result in poor wakefulness maintenance, poor REM sleep regulation, and cataplexy.13,14

PRESENTATION
The onset of narcolepsy is between the ages of 10-25 years
old, though the manifestation of symptoms can begin at any
age.15 EDS is the most common symptom. ThoughItesent
in narcolepsy with and without cataplexy is also associated
with many other disorders, including psychiatric disorders,
neurologic illnesses, and medication side effects.16 Patients
who present with EDS should also be evaluated for fatigue
due to their overlapping presentations.16 One way to distinguish fatigue from EDS is by using the Multiple Sleep Latency Test (MSLT), which is used measuresogical sleepiness;
patients with EDS will show short sleep latencies; MSLT results are normal in fatigue.16 The diagnostic criteria established by ICSD include chronic excessive sleepiness lasting
more than three months, a mean sleep latency less than
or equal to eight minutes, and two or more sleep-onset
rapid-eye-movement periods (SOREMPs).7 Cataplexy is always associated with NT1, and it is pathognomonic of the
disease.17 Patients present with varying degrees of muscle paralysis and weakness in arms, legs, and facial muscles, which can be triggered by strong emotions, such as
laughter.18 Cataplexy attacks last between a few seconds to
minutes, after which the patient may fall asleep.18 Reduction in hypocretin levels leads to a change in metabolism,
which disrupts baseline energy homeostasis, causing obesity, type-II diabetes mellitus, lower body temperature, and
lower blood pressure.18 Other symptoms associated with
narcolepsy include sleep paralysis, sleep-related hallucinations, and sleep fragmentation.15

CURRENT TREATMENT OF NARCOLEPSY
There is no cure for narcolepsy; therefore, treatment is centered around improving daily functioning by decreasing
EDS symptoms, nocturnal sleep disruption, cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis, and
associated comorbidities.1,3,5,8,18 Narcolepsy is typically
treated with wake-promoting drugs and lifestyle
changes.1,3 Patients with mild symptoms may be able to
use solely nonpharmacologic methods. However, most will
require medication.1,3 Lifestyle changes that may improve
narcolepsy symptoms include improving sleep hygiene, creating a structured sleeping schedule, and taking one or two
scheduled naps in the afternoon.1,3 20-minute naps typically improve EDS, though some patients may require
longer naps.1,3
The sustained attention to response task (SART), Epworth sleepiness scale (ESS), and maintenance of wakefulness test (MWT) measure the treatment response to narcolepsy and are used to compare treatments.4 The global
clinical impression of severity (CGI-S) is a six-point scale,
rated using a clinical interview, measuring EDS and cataplexy severity. The CGI-S is used to calculate the global
clinical impression of change (CGI-C), which measures disease improvement with treatment.4 Studies use these tools

to determine the effectiveness of new drugs, develop treatment guidelines, and monitor treatment progression.
Modafinil and armodafinil (the r-enantiomer of
modafinil) are first-line therapies for EDS in narcolepsy.1,3,18 Modafinil promotes wakefulness but does not
treat cataplexy and has low abuse potential.3,18 Modafinil
works by increasing the extracellular concentration of
dopamine in the hypothalamus’ wake-generating sites by
selectively and competitively binding the dopamine transporter.3,18 Some studies suggest that modafinil may be
more effective as split dosing (either 200 mg in the morning
and 200 mg in the afternoon or two doses of 600 mg) rather
than a single dose in the morning.18 Armodafinil has a
longer duration of action than modafinil, and a smaller dose
(100-250 mg/day) is required to be effective.18 The mean
monthly drug-specific pharmacy costs of armodafinil are
lower compared to modafinil.18 Stimulants are indirect
sympathomimetics and are second-line therapy for EDS.
Methylphenidate and amphetamines, including dextroamphetamine, amphetamine-dextromethamphetamine combination, and amphetamine sulfate, promote wakefulness
by increasing the release of dopamine, noradrenaline, and
serotonin and inhibiting the dopamine transporter, which
increases amine concentration in the synapse.18 Rebound
hypersomnia, abuse, and tolerance are potential side effects
of amphetamines, so they are only used under specific circumstances.18 An intermediate-release formulation of
methylphenidate may be used if first-line therapy is unsuccessful.18
Patients who solely use amphetamines for EDS will most
likely have better results and lower risk of recreational
abuse by taking an extended-release formulation, such as
MES-amphetamine (Adderall XR) or lisdexamfetamine
dimesylate (Vyvanse).18 Additionally, patients who partially respond to modafinil or armodafinil and who also
need to maintain wakefulness in the afternoon may need
supplemental,
short-acting
stimulants,
preferably
methylphenidate.18 Additional side effects of amphetamines include cardiac risks, anorexia, insomnia, and appetite suppression.18
Solriamfetol (JZP-110), a dopamine and norepinephrine
reuptake inhibitor, was recently approved to treat EDS in
adults.5 Its efficacy was demonstrated via significant improvements on the MWT in randomized control trials.5,8
It has shown no clinical efficacy in treating cataplexy.5,8
Sodium oxybate, a metabolite of γ-amino butyric acid
(GABA), is a first-line therapy for EDS and cataplexy, sleep
paralysis, severe breathing problems, seizure, loss of consciousness, hypnagogic hallucinations or death.19 Thus,
sale is restricted to certified pharmacies. At doses of six
and nine grams, sleep attack frequency was significantly
reduced. However, it takes at least eight weeks before the
effectiveness of reducing sleepiness becomes apparent.18
Nine-gram doses also decrease nocturnal awakenings.18
Sodium oxybate, taken with Modafinil, shows the greatest
improvement in EDS.18 Sodium oxybate side effects include
confusion, anxiety, dizziness, and nausea.
Recent developments in narcolepsy treatment have been
focused on non-hypocretin and hypocretin-based therapies
and immunotherapy.18 Non-hypocretin therapies being developed include histamine receptor antagonists (such as
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Pitolisant), novel monoaminergic reuptake inhibitors,
GABAB receptor agonists, GABAA receptor modulators,
slow-wave sleep enhancers, TRH and TRH analogs, and
melanin-concentrating hormone receptor modulators.18
Hypocretin-based therapies include cell transplantation,
stem cells, hypocretin peptide replacement, and gene replacement therapy.18 Cell transplantation, stem cells, and
gene replacement therapy have only been studied in animal
models.18 Hypocretin peptide replacement would theoretically work well in type 1 narcoleptic patients, whose disease
is characterized by loss of hypocretin (orexin) neurons.5,18
However, this has not been successful since hypocretin peptides cannot cross the blood-brain barrier significantly to
cause favorable effects.5 Finally, immunotherapy aims to
reverse hypocretin neuronal cell destruction associated
with narcolepsy type I.18 Studies using plasmapheresis, corticosteroids, and intravenous immunoglobulin infusions
have shown variable results, and structured treatment
guidelines have been limited by available research studies
being too small and uncontrolled.18
Pitolisant (Wakix) is a first-in-class non controlled drug
with a novel mechanism of action for narcolepsy treatment,
which sets it apart from preexisting therapies.13,15 It is approved for treatment if narcolepsy type 1 and 2 and is recognized as an orphan drug by the EMA and US Food and
Drug Administration.13 In Phase III trials, Pitolisant decreased the frequency of cataplexy attacks, reduced EDS,
and improved the level of attention on sustained attention
to response tasks.5,18 Pitolisant also significantly reduced
hypnagogic hallucinations and sleep paralysis.5 Its non-inferiority to current treatment options has not been effectively demonstrated. Additional long-term RCTs comparing
Pitolisant to modafinil and sodium oxybate are needed to
elucidate its effectiveness in treatment and possible use as
a possible first-line agent.13

DRUG INFORMATION
Pitolisant is taken orally.1,3,5 Internationally, tablet
strengths are listed as 4.5 mg and 18 mg, whereas the US
tablets are labeled as 4.45 mg and 17.8 mg.1 The initial dose
to treat narcolepsy, including EDS and cataplexy, is 8.9 mg
once daily for one week, increased to 18.8 mg once daily the
following week, and then increased to a maximum dose of
36.5 mg once daily in the third week, based on response.1,3
Doses can be reduced as need by 4.5 mg/day.3 If a dose is
missed, the next dose may be administered the following
morning.1 No rebound effect was reported during clinical
trials.4 The 4.45 mg oral tablets cost $113.70 each.1 The 17.8
mg tablets cost $227.40 each.1
Doses may need to be adjusted under certain conditions.
For CYP2D6 poor metabolizers, the treatment is as above
for the first week, but the maximum dose is 17.8 mg once
daily instead of 36.5 mg once daily.1,5 Significant drug interactions exist with concomitant therapy, and a drug interaction database needs to be consulted before planning a
dosing regimen.1,5 For renal impairment with eGFR 15 to
<60 mL/minute/1.73 m2, the initial dose is at 8.9 mg once
daily for one week, but the maximum dose increase is 17.8
mg once daily. For eGFR < 15 mL/minute/1.73 m2, Pitolisant
is not recommended.1 Pitolisant is contraindicated in in-

stances of severe hepatic impairment and in anyone who
develops hypersensitivity to the drug or any component of
the formulation.1 Avoid use in patients with known QT prolongation or patients who take other agents known for QT
prolongation (e.g. Methadone, Citalopram, Escitalopram,
etc.).1,4 Avoid use in patients with cardiac arrhythmias or at
increased risk of torsades de pointes.1 The risk of adverse
events is greater in those with hepatic or renal impairment.1,4 Renal and hepatic function baseline should be established and monitored as clinically indicated.1 Drug interactions typically include substances that affect the
concentration of CYP2D6 substrates.1,4 CYP2D6 inhibitors
may increase the serum concentration of Pitolisant.1
Pitolisant use with moderate CYP2D6 inhibitors needs to be
monitored, while the dose of Pitolisant needs to be reduced
by half with the use of strong CYP2D6 inhibitors.1 Ajmaline, lumefantrine, and cobicistat may increase the serum
concentration of CYP2D6.1 Antihistamines, tricyclic antidepressants, and mirtazapine may lower the therapeutic effect of Pitolisant.1 Pitolisant may decrease the serum concentration of hormonal contraceptives, and patients should
be advised to use non-hormonal contraceptives while on
Pitolisant.1,4 CYP34A inducers may decrease the serum
concentration of Pitolisant.1 Pitolisant dosing may need to
be doubled over seven days if a new drug is started and
known to be a strong CYP3A4 inducer.
Adverse reactions to Pitolisant in the HARMONY I trial
included headache (35%), insomnia (10%), abdominal discomfort or pain (6%), and nausea (6%).1,2 One subject had
a serious adverse event of abdominal discomfort related to
Pitolisant.2 In a retrospective chart review, the most common adverse events were epigastric and abdominal pain
(15.4%), increased appetite (14.1%), weight gain (14.1%),
headache (12.8%), insomnia (11.5%), and anxiety (9%).2
Other studies have shown increased heart rate (3%), anxiety
(5%), hallucinations (3%), irritability (3%), sleep disturbance (3%), cataplexy (2%), xerostomia (2%), decreased appetite (3%), musculoskeletal pain (5%), and upper respiratory tract infection (5%).1 At very high doses (108-216 mg),
a slight QTc interval prolongation has been observed.1,3,4
Migraine, abnormal behavior, abnormal dreams, sleep
paralysis, sleep-talking, bipolar disorder, depressed mood,
epilepsy, fatigue, anhedonia, pruritus, and suicidal ideation
have also been observed, but with an unknown frequency.1
Adverse event during pregnancy was noted in some animal
studies, but further data collection monitoring Pitolisant’s
effects in pregnancy and infancy is ongoing.1,4 The presence of Pitolisant in breast milk is unknown.1 No drug abuse
potential was observed with Pitolisant.3

MECHANISM OF ACTION
Pitolisant is orally active and a potent, selective histamine
H3-receptor antagonist/inverse agonist.1 H3-receptors are
primarily located in the cerebral cortex, hypothalamus hippocampus, and basal ganglia.3 Pitolisant’s blockade of histamine auto-receptors increases histamine concentration
and histaminergic activity in the brain.1,4 Histaminergic
neurons have widespread projections throughout the brain
that play a major role in arousal.1,2 Histaminergic neurons
of the tuberomammillary nucleus of the hypothalamus are
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particularly important in maintaining vigilance under certain environmental and behavioral conditions.2 Increased
histamine concentration in the hypothalamus is thought
to contribute to Pitolisant’s role in treating EDS and cataplexy.4 Pitolisant also modulates other neurotransmitters,
increasing acetylcholine, noradrenaline, and dopamine release in the brain.1,3

PHARMACOKINETICS/ PHARMACODYNAMICS
Pitolisant enhances the level and duration of wakefulness
and alertness, according to the MWT and SART, both of
which objectively measure the ability to sustain wakefulness.1 Pitolisant is absorbed rapidly after oral administration, reaching peak plasma concentration approximately
three hours after administration.1,3,4 Pitolisant has a
plasma half-life of about 10-12 hours and reaches a steadystate in about five-six days.3,4 Pitolisant has approximately
equal distribution between red blood cells and plasma and
exhibits high serum protein-binding (>90%).1,3,4 Pitolisant
is primarily eliminated in the urine (63%) through an inactive, non-conjugated metabolite (BP2.951) and a glycineconjugated metabolite.3,4 Pitolisant is also excreted
through expired air (25%) and in feces (<3%).4 CYP3A4 and
CYP2D6 form the major non-conjugated metabolites of
Pitolisant, including hydroxylated derivatives and cleaved
forms found in serum and urine.1,3 The primary inactive
metabolite formed by CYP3A4 and CYP2D6 is 5-aminovaleric acid.3 The major conjugated metabolites are two
glycine conjugates of an acid metabolite and a glucuronide
of a ketone metabolite.1 In vitro studies of Pitolisant have
suggested it to be a CYP3A4, CYP1A2, and CYP2B6 inducer,
along with CYP2D6 and OCT1 inhibitors.3,4 In vitro studies
have also suggested that Pitolisant is not a substrate or an
inhibitor of human P-glycoprotein and breast cancer resistance protein.3,4 AUC0-∞ is increased by about 2.3 when
Pitolisant dose is doubled from 27 to 54 mg.3,4 In patients
68 to 80 years old, Pitolisant’s pharmacokinetics is similar
to that in younger patients.3,4 Slight variation in pharmacokinetics is shown in patients over 80 years old, but it has no
clinical relevance.4 AUC and Cmax are typically increased by
a factor of 2.5, without impacting the half-life, in patients
with renal impairment (creatine clearance between 15 to 89
mL/min).4 No significant changes were seen with mild hepatic impairment (Child-Pugh A). However, AUC increased
by 2.4, and the half-life doubled in patients with moderate
hepatic impairment (Child-Pugh B).4

CLINICAL STUDIES: SAFETY AND EFFICACY
PHASE II STUDIES

Three-phase II trials were undertaken to demonstrate the
efficacy and safety of Pitolisant in narcoleptic patients. The
P05-03 study was a single-blind, multicenter, placebo-controlled study, in which 22 narcoleptic patients were assigned a seven-day course of a placebo, followed by a daily
regimen of 40 mg Pitolisant taken in the morning. In evaluating response to active treatment, participants saw a notable reduction in their Epworth Sleepiness Scale (ESS)
scores from a baseline of 17.55±3.89 to 11.81±6.11. These

results represent a 4.86±5.12 reduction in ESS compared
to placebo) and a 5.85±5.51 reduction relative to baseline.
The P05-03 study noted no significant decrease in ESS relative to baseline (p>0.05).20 The P06-06 study was run as
a multicenter, open-label Phase II trial, wherein 26 participants were evaluated for response to an increasing dose of
Pitolisant.20 This escalating regimen involved participants
receiving either 10, 20, or 40 mg daily dosages for a maximum of nine months. Participants were evaluated at one,
three, and nine-month intervals, demonstrating a reduction in ESS of 4.8, 5.3, and 6.9 points, respectively.20
INITIAL HARMONY TRIALS

Harmony I analyzed 110 narcoleptic patients from 32 treatment centers across Europe, 95 of which were randomly
assigned to either Pitolisant (n=32), modafinil (n=33), or
placebo (n=30) for eight weeks. The efficacy of Pitolisant
was shown primarily via two double-blind, multicenter, parallel-group, placebo-controlled randomized trials, every
eight weeks in duration with a flexible dosing schedule. In
each study, researchers defined the measure of efficacy as
a minimal clinically relevant difference in final ESS score
between treatment and placebo groups of (3 points (20).
Treatment schedule over eight weeks: three weeks of flexible dosing (10, 20, or 40 mg/day of Pitolisant; 100, 200, or
400 mg/day of Modafinil), followed by five weeks of a steady
dose of the assigned therapy. By the end of eight weeks,
mean ESS score reductions were -3.4±4.2 for the placebo
group, -5.8±6.2 in the Pitolisant group, and -6.9±6.2 in the
Modafinil group. Thus, Pitolisant demonstrated a significant improvement in outcome relative to placebo (a difference of -3.3 with a 95% CI of -5.83 to -0.83; p=0.024). This
superiority was further demonstrated by differing measures
of the Maintenance of Wakefulness Test (MWT) between the
Pitolisant and placebo groups, demonstrating a difference
of 1.47 (95% CI of 1.01 to -2.14; p=0.044). However, Harmony I did not demonstrate Pitolisant’s superiority relative
to modafinil, showing instead a mean ESS difference of only
0.12 (95% CI of -2.5 to 2.7; p>0.250) between these groups.
Thus, the authors of Harmony I demonstrated the efficacy
of Pitolisant (up to a 40 mg daily dose) relative to placebo,
but not relative to standard Modafinil regimens.20
Harmony Ibis was the second RCT to demonstrate
Pitolisant’s efficacy in treating narcolepsy.20 It evaluated
165 participants, randomly dividing them into Pitolisant
(n=67), Modafinil (n=65), or placebo (n=33) groups. This
study used a flexible dosing model for the first three weeks
of treatment: 10 or 20 mg daily of Pitolisant; or 100, 200, or
400 mg daily of Modafinil. This period of flexible dosing was
followed by five weeks of stable dosing. Following the eightweek regimen, mean ESS score reductions were: 3.6±5.6 for
placebo, -4.6±4.6 for Pitolisant, and -7.8±5.9 for Modafinil.
Whereas Pitolisant demonstrated efficacy relative to baseline in Harmony I, Harmony Ibis noted a difference in mean
ESS scores of only -1.94 (95% CI of -4.005 to -0.07; p=0.06)
between Pitolisant and placebo treatments, thus failing to
meet the criterion for efficacy of ≥3 points. Again, in evaluating the treatments’ effect on ESS scores, non-inferiority
of Pitolisant relative to Modafinil could not be established
in this RCT either, as data demonstrate a difference of -2.75
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(95% CI -4.48 to -1.02), which failed to meet the pre-established cutoff of three points. Rather, when subjected to
an unplanned superiority analysis of Modafinil relative to
Pitolisant, Modafinil therapy demonstrated a much greater
reduction in the mean ESS score (difference of -2.75;
p<0.002).20
Interestingly, Harmony III demonstrated a high participant drop-out of nearly 33%, with nearly 20% of those
individuals citing “insufficient benefit.”21 However, among
participants who completed the twelve-month treatment
course, nearly 67% were deemed responders, with either an
end-treatment ESS ≤ 10 or a reduction in ESS ≥ 3; the remaining 33% demonstrated a normalized ESS (i.e. ESS ≤
10).21
PHASE III STUDIES

The P11-05 study (Harmony CTP) was a double-blind, randomized, parallel-group phase III study seeking to evaluate
the effect of Pitolisant vs. placebo on the reduction in cataplectic episodes in narcoleptic patients, measured as the
number of episodes per week.17 One hundred forty-four
narcoleptic patients were divided into Pitolisant and
placebo groups, each of which was given a seven-week
treatment regimen, consisting of three weeks of flexible
Pitolisant dosing (5, 10, or 20 mg daily) followed by four
weeks of stable dosing (5, 10, 20, or 40 mg daily). The primary analysis demonstrated a significant reduction in cataplexy episodes for the Pitolisant group. Compared to baseline, the stable dosing period showed a reduction in
cataplexy episodes per week from 9.15 to 3.28 in the
Pitolisant group and 7.31 to 6.79 for the placebo group. Additionally, after Harmony CTP, the percentage of participants demonstrating a high rate of cataplectic episodes (defined as >15 episodes/week) was significantly higher in the
placebo group (23.5%; 95% CI of 12 to 51) relative to the
Pitolisant group (5.6%; 95% CI of 3 to 54). In evaluating
Pitolisant’s effect on EDS, Harmony CTP demonstrated a
significant reduction in mean ESS scores relative to
placebo: Pitolisant group showed a change of -5.4±4.3
(p<0.001), while the placebo group showed a mean ESS
score change of -1.9±4.3 (p<0.001).17
While data have yet to be fully published, the P10-01
study (Harmony IV)- the most recent RCT evaluating the effect of Pitolisant therapy on EDS relative to placebo, with
add-on sodium oxybate- demonstrated no significant differences about daytime sleepiness (ESS score reduction),
rates of cataplexy, or quality of life.20 This study evaluated
48 narcoleptic patients receiving a 5 mg daily dose of
Pitolisant, gradually increased to 40 mg daily during the
first five weeks, followed by a steady daily dose for one
month. Results demonstrated a mean EDS score change of
-2.6 (p=0.595) for Pitolisant and -2.1 (p=0.595) for placebo
group.20
SAFETY

Setnik et al. devised a single dose, randomized, doubleblind, active- and placebo-controlled, four sequences, fourperiod crossover study to evaluate abuse potential and overall clinical safety of Pitolisant for narcoleptic patients, with

or without, cataplexy.22 This study recruited only participants with a history of recreational stimulant use at least
once in the past eight weeks or ten times in the past year.
Researchers first screened participants based on their ability to discern a 60 mg Phentermine dose from placebo, randomly assigning the order in which each was received. Provided the participant could distinguish between the two
correctly, they were assigned to one of four regimens in
the double-blind treatment phase, differing only in order
of dosing regimen, with a seven-day washout between each
medication. Each participant received 35.6 mg Pitolisant,
213.6 mg Pitolisant, 60 mg Phentermine HCl, and a placebo.
Participants were evaluated using the Drug Liking Visual
Analog Scale (DLVAS), involving subjective rankings of each
drug’s appeal to participants, with a score of 0 meaning
“strong disliking” and a score of 100 meaning “strong liking.” Phentermine demonstrated a vastly higher DLVAS
score when compared with placebo (+22.7; p<0.0001),
Pitolisant 35.6 mg (+21.4; p<0.0001), and Pitolisant 213.6
mg (+19.7; p<0.0001), suggesting a significant difference
in addiction potential between Phentermine and Pitolisant.
Compared to placebo, neither Pitolisant 35.6 mg nor
Pitolisant 213.6 mg showed a difference in DLVAS score (0.0
with p<0.0001; 0.0 with p=0.0013, respectively). In terms of
adverse effects, the most commonly reported side effects
were headache (three participants in the placebo group,
two in the Pitolisant 213.6 mg group) and vomiting (one in
Pitolisant 35.6 mg group). However, these adverse effects
appear to be dose-related, and it is important to note that
no study participant withdrew from the study due to adverse side effects. All other recorded adverse effects were
related to phentermine.22 A meta-analysis conducted by
Lehert et al. examined 10 RCTs comparing the efficacy of
Pitolisant relative to modafinil in cataplectic and non-cataplectic patients.23 This was done by comparing ESS and
MWT scores; differences in ESS and MWT scores were statistically insignificant, but, in cataplectic patients, results
demonstrated Pitolisant superiority to Modafinil. Additionally, with a risk ratio of 0.86±0.4 in favor of Pitolisant, there
is evidence that Pitolisant is safer than Modafinil in treating
narcolepsy.23
Over the past few years, questions have been raised (notably by the International Conference on Harmonization
(ICH) and the Comprehensive in vitro Pro-arrhythmia Assay
(CiPA)) regarding Pitolisant’s inhibition of calcium and late
INa ion channels, with concern that this could lead to prolonged QTc.24 While non-clinical data presented by these
groups certainly refutes this idea (especially at the standard
20 and 40 mg doses of Pitolisant), analysis by Ligneau et al.
acknowledges the need for further study on Pitolisant’s effect on cardiac rhythm and other conditions that can predispose or contribute to QT prolongation.24

CONCLUSION
Narcolepsy is a debilitating sleep disorder that presents
with EDS and cataplexy in some patients. Pharmacologic
treatment options include Modafinil and Armodafinil for
EDS and sodium oxybate for cataplexy secondary to narcolepsy. Pitolisant, an antagonist/inverse agonist of H3R,
is a novel drug currently used in Europe and United States
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to treat EDS and cataplexy in narcolepsy. Clinical trials in
phase II and phase III have shown mean ESS score decreases
and reductions in cataplexy episodes in participants administered Pitolisant. Based on comparative studies, recent evidence has shown that Pitolisant is non-inferior to Modafinil
in the treatment of EDS but superior to Modafinil in reducing cataplexy.23,25
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Table 1. Clinical Efficacy and Safety
Study
Name

Groups Studied and Intervention

Results and Findings

Conclusions

P05-03

22 participants were randomly
assigned to Pitolisant and placebo
regimens, each of which lasted
seven days. Primary outcomes
were measured using the Epworth
Sleepiness Scale (ESS).

Participants saw a notable reduction in ESS scores
from a baseline of 17.55±3.89 to 11.81±6.11.
Pitolisant treatment represents a 4.86±5.12 reduction
in ESS compared to placebo, and a 5.85±5.51
reduction relative to baseline.

Pitolisant
demonstrates
no statistically
significant
benefit over
baseline.

P06-06

26 participants were administered
varying doses of Pitolisant for a
maximum of nine months to
evaluate efficacy of escalated
doses. Primary outcomes were
measured using the ESS.

Participants received either 10, 20, or 40 mg daily
doses for a maximum of nine months and were
evaluated at one-, three-, and nine-month intervals.
These regimens resulted in ESS score reductions of
4.8, 5.3, and 6.9 points, respectively.

The efficacy of
Pitolisant is
dosedependent,
suggesting 40
mg would
demonstrate
most
therapeutic
value.

Harmony
I

95 participants from 32 centers
across Europe were randomly
assigned to either Pitolisant
(n=32), Modafinil (n=33), or
placebo (n=30) for eight weeks, to
evaluate efficacy of Pitolisant
relative to standard Modafinil
therapy. Primary outcomes were
measured using the ESS.

Treatment schedule over eight weeks: three weeks of
flexible dosing (10, 20, or 40 mg/day of pitolisant; 100,
200, or 400 mg/day of modafinil) followed by five
weeks of a steady dose of either Pitolisant or
Modafinil. By the end of eight weeks, mean ESS score
reductions were -3.4±4.2 for placebo, -5.8±6.2 for
Pitolisant, and -6.9±6.2 for Modafinil.

No
demonstration
of Pitolisant’s
superiority
relative to
Modafinil.

Harmony
Ibis

165 participants were divided
randomly into Pitolisant (n=67),
Modafinil (n=65), or placebo
(n=33) groups to evaluate efficacy
of Pitolisant relative to standard
Modafinil therapy. Primary
outcomes were measured using
the ESS.

Flexible dosing for first three weeks of treatment: 10
or 20 mg daily of Pitolisant; or 100, 200, or 400 mg
daily of Modafinil. Flexible treatment was followed by
five weeks of stable dosing. The mean ESS score
reductions follow the eight-week regimen: -3.6±5.6
for placebo, -4.6±4.6 for Pitolisant, and -7.8±5.9 for
Modafinil). Difference in mean ESS scores of only
-1.94 (95% CI of -4.005 to -0.07; p=0.06) between
Pitolisant and placebo, thus failing to meet efficacy
criterion of a difference of at least three ESS points.
Non-inferiority of Pitolisant relative to Modafinil
could not be established, as data demonstrate a
difference of -2.75 (95% CI -4.48 to -1.02) which failed
to meet the pre-established cutoff of three points

When
subjected to
an unplanned
superiority
analysis of
Modafinil
relative to
Pitolisant, the
Modafinil
group
demonstrated
a much
greater mean
ESS score
reduction.
Thus,
Pitolisant
failed to
demonstrate
superiority to
both placebo
and Modafinil
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Harmony
III

102 participants with narcolepsy,
with or without cataplexy, were
enrolled in an open-label trial, 68
of which completed a twelvemonth treatment period. Primary
endpoint was incidence of
Treatment-Emergent Adverse
Effects (TEAE) at twelve months,
while secondary endpoints were
measured using the (ESS).

Participants started with one week of 5 mg Pitolisant
daily, followed by a week of 10 mg daily, followed by a
week of 20 mg, subject to safety and tolerability. After
a month, the investigator could titrate the dose to
40mg if lower doses were not deemed efficacious.
Commonly-reported TEAEs rwere headache (11.8%),
insomnia (8.8%), weight gain (7.8%), anxiety (6.9%),
depressed mood (4.9%), and nausea (4.9%). Also
reported were seven instances of severe adverse
effects, all of which were deemed unrelated to
Pitolisant therapy. Nearly 67% of those who finished
the treatment regimen were deemed responders with
either an end-treatment ESS ≤ 10 or a reduction in ESS
≥ 3, while the remaining 33% demonstrated a
normalized ESS (i.e. ESS ≤ 10).

The vast
majority of
TEAEs
reported while
on Pitolisant
therapy were
mild to
moderate;
only 6.55%
were severe
and related to
the study
drug. In terms
of secondary
goals,
Pitolisant
demonstrated
a high
response rate
at therapeutic
dosages.

Harmony
CTP
(P11-05)

145 narcoleptic participants were
divided into Pitolisant and placebo
groups, each of which was given a
seven-week regimen consisting of
three weeks of flexible Pitolisant
dosing (5, 10, or 20 mg daily)
followed by four weeks of stable
dosing (5, 10, 20, or 40 mg daily).
This study sought to evaluate the
effect of Pitolisant versus placebo
on reducing cataplectic episodes
in narcoleptic patients, measured
as the number of episodes per
week. Secondary objectives
evaluated the effect of Pitolisant
on EDS, measured using the ESS.

When measured relative to the frequency of cataplexy
during a two-week baseline period, the stable dosing
period showed a reduction in episodes per week for
the Pitolisant group from 9.15 to 3.28, and the placebo
group from 7.31 to 6.79. At the study’s conclusion, the
percentage of participants demonstrating a high
frequency of cataplectic episodes (defined as >15
episodes/week) was significantly higher in the placebo
group (23.5%; 95% CI of 12 to 51) relative to the
Pitolisant group (5.6%; 95% CI of 3 to 54). Harmony
CTP demonstrated significant reduction in mean ESS
scores relative to the placebo group. The placebo
group showed a mean ESS score change of -1.9±4.3
(p<0.001) relative to baseline values, while the
Pitolisant group exhibited a change of -5.4±4.3
(p<0.001).

There was a
statistically
significant
reduction in
cataplectic
episodes in
the Pitolisant
group relative
to placebo.
Additionally,
relative to
placebo,
Pitolisant
showed a
statistically
significant
reduction in
overall EDS.
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